T. Uchimoto

发表

Remarkable response to fluorouracil, leucovorin, oxaliplatin, and irinotecan therapy in urothelial cancer of the renal pelvis: a case report

K. Takahara, T. Matsunaga, H. Azuma, 2017, Journal of Medical Case Reports.

Prostatic Bleeding after Prostatic Biopsy Effects Oncological Outcomes with Laparoscopic Radical Prostatectomy.

H. Uehara, K. Takahara, T. Matsunaga, 2016, Asian Pacific journal of cancer prevention : APJCP.

Influence of the Body Mass Index and its Effect on Tumor Characteristics and Survival among a Population with Access to Surgical Management of Upper Tract Urothelial Carcinoma

T. Tsuzuki, Masashi Kato, H. Azuma, 2019, Current Urology.

Novel bladder preservation therapy with Osaka Medical College regimen.

K. Takahara, H. Azuma, K. Komura, 2015, The Journal of urology.

Serum C-reactive Protein Level Predicts Overall Survival for Clear Cell and Non-Clear Cell Renal Cell Carcinoma Treated with Ipilimumab plus Nivolumab

K. Takahara, R. Shiroki, H. Azuma, 2022, Cancers.

Feasibility of photodynamic diagnosis for challenging TUR- Bt cases including muscle invasive bladder cancer, BCG failure or 2nd-TUR.

H. Uehara, K. Takahara, H. Azuma, 2015, Asian Pacific journal of cancer prevention : APJCP.

Concurrent palliative radiation with pembrolizumab for platinum-refractory urothelial carcinoma is associated with improved overall survival

K. Takahara, R. Shiroki, H. Azuma, 2022, Clinical and translational radiation oncology.

Significance of second progression‐free survival in patients with advanced urothelial cancer who received platinum‐based combination chemotherapy followed by pembrolizumab

K. Harada, H. Azuma, T. Inamoto, 2022, International journal of urology : official journal of the Japanese Urological Association.

Dual Gas Treatment With Hydrogen and Carbon Monoxide Attenuates Oxidative Stress and Protects From Renal Ischemia-Reperfusion Injury.

T. Takai, H. Hirano, H. Azuma, 2018, Transplantation proceedings.

Single session of high-intensity focused ultrasound for localized prostate cancer: treatment outcomes and potential effect as a primary therapy

K. Takahara, H. Azuma, K. Komura, 2013, World Journal of Urology.

Increased BUB1B/BUBR1 expression contributes to aberrant DNA repair activity leading to resistance to DNA-damaging agents

Y. Hirose, Tomohito Tanaka, H. Uehara, 2021, Oncogene.

Risk Classification for Overall Survival by the Neutrophil–Lymphocyte Ratio and the Number of Metastatic Sites in Patients Treated with Pembrolizumab—A Multicenter Collaborative Study in Japan

S. Egawa, Tomohito Tanaka, H. Uehara, 2021, Cancers.

Early Prostate-Specific Antigen (PSA) Change at Four Weeks of the First-Line Treatment Using Abiraterone and Enzalutamide Could Predict Early/Primary Resistance in Metastatic Castration-Resistant Prostate Cancer

S. Egawa, Tomohito Tanaka, H. Uehara, 2021, Cancers.

Prognostic impact of C-reactive protein-albumin ratio for the lethality in castration-resistant prostate cancer

Tomohito Tanaka, H. Uehara, K. Takahara, 2019, Medical Oncology.

245 MicroRNA-145 mediates the inhibitory effect of adipose-derived stem cells on androgen-independent prostate cancer

K. Takahara, H. Azuma, T. Inamoto, 2016 .

Comparison of Radiographic Progression-Free Survival and PSA Response on Sequential Treatment Using Abiraterone and Enzalutamide for Newly Diagnosed Castration-Resistant Prostate Cancer: A Propensity Score Matched Analysis from Multicenter Cohort

Tomohito Tanaka, H. Uehara, K. Takahara, 2019, Journal of clinical medicine.

A Panel of MicroRNA Signature as a Tool for Predicting Survival of Patients with Urothelial Carcinoma of the Bladder

Y. Akao, H. Uehara, K. Takahara, 2018, Disease markers.

Risk stratification for the prediction of overall survival could assist treatment decision‐making at diagnosis of castration‐resistant prostate cancer: a multicentre collaborative study in Japan

S. Egawa, Tomohito Tanaka, H. Uehara, 2020, BJU international.

Effectiveness of pembrolizumab in patients with urothelial carcinoma receiving proton pump inhibitors.

S. Egawa, T. Kamoto, N. Terada, 2022, Urologic oncology.

The novel bladder preservation therapy BOAI-CDDP-radiation (OMC-regimen): a new treatment option for invasive bladder cancer patients with lymph node metastasis.

K. Takahara, H. Azuma, K. Komura, 2014, International journal of oncology.

Prognostic value of the fluctuation in the neutrophil-lymphocyte ratio at 6 weeks of pembrolizumab treatment is specific to the clinical response in metastatic urothelial carcinoma.

S. Egawa, Tomohito Tanaka, H. Uehara, 2022, Urologic oncology.

Efficacy of pembrolizumab and comprehensive CD274/PD-L1 profiles in patients previously treated with chemoradiation therapy as radical treatment in bladder cancer

Y. Hirose, S. Egawa, Tomohito Tanaka, 2022, Journal for ImmunoTherapy of Cancer.

Preoperative Measurement of the Modified Glasgow Prognostic Score Predicts Patient Survival in Non-Metastatic Renal Cell Carcinoma Prior to Nephrectomy

H. Uehara, K. Takahara, T. Matsunaga, 2017, Annals of Surgical Oncology.

Incidence of urethral stricture after bipolar transurethral resection of the prostate using TURis: results from a randomised trial

H. Uehara, K. Takahara, H. Azuma, 2015, BJU international.

Could transurethral resection of the prostate using the TURis system take over conventional monopolar transurethral resection of the prostate? A randomized controlled trial and midterm results.

H. Uehara, K. Takahara, H. Azuma, 2014, Urology.

Intravesical administration of exogenous microRNA-145 as a therapy for mouse orthotopic human bladder cancer xenograft

Y. Akao, H. Uehara, K. Takahara, 2015, Oncotarget.

microRNA-145 Mediates the Inhibitory Effect of Adipose Tissue-Derived Stromal Cells on Prostate Cancer.

H. Uehara, T. Nakagawa, K. Takahara, 2016, Stem cells and development.

Re‐challenging chemotherapy after pembrolizumab in platinum‐refractory urothelial carcinoma

T. Adachi, S. Egawa, K. Takahara, 2022, BJU international.

Prognostic model with alkaline phosphatase, lactate dehydrogenase and presence of Gleason pattern 5 for worse overall survival in low-risk metastatic hormone-sensitive prostate cancer.

S. Egawa, Shunsuke Tsuzuki, Masayuki Tomita, 2021, Japanese journal of clinical oncology.

Real-world survival outcome comparing abiraterone acetate plus prednisone and enzalutamide for nonmetastatic castration-resistant prostate cancer.

K. Takahara, R. Shiroki, Shunsuke Tsuzuki, 2023, Cancer medicine.

The novel bladder preservation therapy BOAI-CDDP-radiation (OMC-regimen): a new treatment option for invasive bladder cancer patients with lymph node metastasis.

K. Takahara, H. Azuma, K. Komura, 2014, International journal of oncology.